Phase I (2000-06)

in page functions

Gavi's first five-years focused on getting funds to countries quickly to extend the reach and quality of immunisation programmes

In Gavi's first six years, the Vaccine Alliance concentrated on two primary areas:

  1. supply of new and underused vaccines;
  2. strengthening vaccine delivery systems.

From 2000-06, Gavi's new and underused vaccine support (NVS) focused on three underused vaccines: hepatitis B (hepB), Haemophilus influenzae type b (Hib) and yellow fever.
 

Support was provided in the form of five-year grants with the expectation that countries would increase their national contribution, leading to eventual financial sustainability.

Delivery systems were improved through Gavi's injection safety support (INS) initiatives. As most infections result from the re-use of equipment, Gavi enabled the supply of disposable auto-disable (AD) syringes for all vaccines to all countries. In addition to minimising infection risk, this helped to drive down the price of AD syringes and increased vaccine demand.

Incentives to immunise more children were given through performance-based funding known asimmunisation services support (ISS) with countries receiving extra money per additional child immunised.

Gavi catalyses new injection safety standards

In Gavi’s first 10 years, 58 countries successfully applied for injection safety support. All but two continued to use auto-disposable syringes even after Gavi's support stopped.


 

Learn more... 

Uganda INS 2009 AD syringes box

More on this topic

US$ 80-100 billion

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

More facts...

close icon

modal window here